<DOC>
	<DOCNO>NCT01306591</DOCNO>
	<brief_summary>Age-related macular degeneration ( AMD ) one primary blind eye disease among people 65 year China . The anti-VEGF antibody treatment prove useful Neovascular Age-related Macular Degeneration ( nAMD ) many study . Bevacizumab available low-cost type anti-VEGF drug currently China . This study multi-center , randomize trial Bevacizumab effective dose safety nAMD . This study explore effective therapeutic approach majority patient China bear establish suitable treatment China .</brief_summary>
	<brief_title>Bevacizumab Neovascular Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Clinical diagnosis neovascular Agerelated macular degeneration Signed informed consent No ocular fundus disease</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>neovascular age-related macular degeneration</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Multicenter Randomized Study</keyword>
</DOC>